Reduced cannabis use after low-dose naltrexone addition to opioid detoxification

Journal of Clinical Psychopharmacology

Volumn 30, Issue 4, 2010, Pages 476-478

  Mannelli, Paolo ^a   Peindl, Kathi ^a   Patkar, Ashwin A ^a   Wu, Li Tzy ^a   Pae, Chi Un ^b   Gorelick, David A ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b The Catholic University of Korea   (South Korea)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; METHADONE; NALTREXONE; OPIATE; PLACEBO; NARCOTIC ANTAGONIST;

DETOXIFICATION; FISHER EXACT TEST; LETTER; PRIORITY JOURNAL; SELF REPORT; TREATMENT OUTCOME; DOSE RESPONSE; FOLLOW UP; HUMAN; MARIJUANA ABUSE; OPIOID-RELATED DISORDERS; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL MODEL;

DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MARIJUANA ABUSE; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77955163569     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181e5c168     Document Type: Letter

References (16)

1. Epstein DH, Preston KL. Does cannabis use predict poor outcome for heroin-dependent patients on maintenance treatment? Past findings and more evidence against. Addiction. 2003;98:269-279.
2. Raby WN, Carpenter KM, Rothenberg J, et al. Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence. Am J Addict. 2009;18:301-308.
3. Budney AJ, Roffman R, Stephens RS, et al. Marijuana dependence and its treatment. Addict Sci Clin Pract. 2007;4:4-16.
4. Haney M. Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers. Neuropsychopharmacology. 2007;32: 1391-1403.
5. Mannelli P, Patkar AA, Peindl K, et al. Early outcomes following low dose naltrexone enhancement of opioid detoxification. Am J Addict. 2009;18:109-116.
6. Moeller KE, Lee KC, Kissack JC. Urine drug screening: practical guide for clinicians. Mayo Clin Proc. 2008;83:66-76.
7. Handelsman L, Cochrane KJ, Aronson MJ, et al. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse. 1987;13:293-308.
8. Muntoni AL, Pillolla G, Melis M, et al. Cannabinoids modulate spontaneous neuronal activity and evoked inhibition of locus coeruleus noradrenergic neurons. Eur J Neurosci. 2006;23:2385-2394.
9. Noble A, Best D, Man LH, et al. Self-detoxification attempts among methadone maintenance patients: what methods and what success? Addict Behav. 2002;27:575-584.
10. Solinas M, Panlilio LV, Tanda G, et al. Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats. Neuropsychopharmacology. 2005;30:2046-2057.
11. Ghozland S, Matthes HW, Simonin F, et al. Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J Neurosci. 2002;22:1146-1154.
12. Justinova Z, Tanda G, Munzar P, et al. The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys. Psychopharmacology (Berl). 2004;173:186-194.
13. Haney M, Bisaga A, Foltin RW. Interaction between naltrexone and oral THC in heavy marijuana smokers. Psychopharmacology (Berl). 2003;166:77-85.
14. Bahremand A, Shafaroodi H, Ghasemi M, et al. The cannabinoid anticonvulsant effect on pentylenetetrazole-induced seizure is potentiated by ultra-low dose naltrexone in mice. Epilepsy Res. 2008;81:44-51.
15. Paquette J, Olmstead MC. Ultra-low dose naltrexone enhances cannabinoid-induced antinociception. Behav Pharmacol. 2005;16:597-603.
16. Paquette JJ, Wang HY, Bakshi K, et al. Cannabinoid-induced tolerance is associated with a CB1 receptor G protein coupling switch that is prevented by ultra-low dose rimonabant. Behav Pharmacol. 2007;18:767-776.